Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18179630 | 0.82 | C5AR1 (0.39) | P2RX7C5AR1ALDH1A1ALOX15TSHR | |
| SCHEMBL18179627 | 0.82 | DDB1 (0.43) | P2RX7C5AR1ALOX15DDB1CRBN | |
| SCHEMBL16834010 | 0.82 | ALDH1A1 (0.43) | C5AR1ALDH1A1MAPT | |
| SCHEMBL18179624 | 0.77 | DDB1 (0.40) | P2RX7ALDH1A1DDB1CRBN | |
| Hydrochloric Acid SCHEMBL1609149 | 0.73 | ADRB1 (0.44) | C5AR1ALDH1A1ALOX15TSHR | |
| SCHEMBL15826554 | 0.72 | FAAH (0.43) | DPP4NR1H2NR1H3ALDH1A1ALOX15 | |
| SCHEMBL30265954 | 0.72 | FAAH (0.43) | DPP4NR1H2NR1H3ALDH1A1ALOX15 | |
| SCHEMBL23729048 | 0.72 | ALDH1A1 (0.39) | C5AR1ALDH1A1ALOX15TSHR | |
| SCHEMBL24631896 | 0.71 | ALDH1A1 (0.40) | C5AR1DPP4NR1H2NR1H3ALDH1A1 | |
| SCHEMBL20365239 | 0.70 | ALDH1A1 (0.40) | C5AR1DPP4NR1H2NR1H3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862734-B2 | Metal-ligand complex, olefin polymerization catalyst derived therefrom, and olefin polymerization method utilizing the catalyst | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160311837-A1 | METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST | DOW GLOBAL TECHNOLOGIES LLC | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311837-A1 | METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST | OPRM1, WASF2, WEE1 | P2RX7 4042/4885C5AR1 2005/4885DPP4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.